Skip to main content
Premium Trial:

Request an Annual Quote

CDC Develops Test for Simultaneous Detection of COVID-19, Flu

NEW YORK – The US Centers for Disease Control and Prevention has designed a new assay that can simultaneously detect the SARS-CoV-2 coronavirus and the influenza virus, and is seeking Emergency Use Authorization for it from the US Food and Drug Administration, CDC Director Robert Redfield told a congressional subcommittee on Thursday.

In prepared remarks for a hearing before the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, Redfield said that it is unclear how long the COVID-19 pandemic will last but that "COVID-19 activity will continue for some time." Similarly, the impact the pandemic will have on the upcoming flu season is unclear, but "if there is substantial COVID-19 and seasonal influenza activity at the same time, this could place a tremendous burden on the healthcare system and result in many illnesses, hospitalizations, and deaths."

Many predict that a second wave of coronavirus cases could hit in the fall during the start of the flu season.

In preparation for such a scenario, the CDC is seeking EUA from the FDA for a new assay that can simultaneously detect SARS-CoV-2 and influenza, as "determining if influenza or SARS-CoV-2 is causing the infection is also important to clinical treatment, infection control, and community mitigation efforts," Redfield said.

As of Thursday afternoon, there were almost 1.9 million cases of COVID-19 confirmed in the US and nearly 109,000 deaths from the disease.

A couple of diagnostic panels that test for COVID-19 and influenza already exist in the US. For example, a PCR-based respiratory panel from BioMérieux's BioFire Diagnostics business that can detect the coronavirus and 20 other viral and bacterial respiratory pathogens, including various influenza A subtypes, received FDA EUA in early May. Also, an RT-PCR-based respiratory panel from Qiagen that includes SARS-CoV-2 and 20 other viral and bacterial pathogens, including influenza A and B types, obtained FDA EUA in March. 

An assay from CDC was the first test to be granted EUA from the FDA for SARS-CoV-2. Problems quickly arose with the test, however, when some labs reported problems with the reagents and could not implement the test. 

The CDC did not immediately respond to a request for comment on the new test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.